|Bid||0.00 x 1000|
|Ask||114.27 x 1400|
|Day's Range||109.67 - 113.00|
|52 Week Range||36.15 - 151.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.59|
The biotech company expects to report data from phase 3 studies of its coronavirus vaccine candidate in the coming weeks. The troubles of rivals AstraZeneca (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) offer CureVac an opportunity to become a leader in Europe. Several European countries temporarily suspended use of the AstraZeneca vaccine last month after some vaccinated individuals developed blood clots.
The COVID-19 vaccine by German biotech firm CureVac candidate should be "ready" in Europe by the end of May, while Europe's medicines agency will finish its assessment of Russia's Sputnik in June, the head of Italy's medicines agency AIFA said on Wednesday. "With CureVac we are at a very good stage, we expect it to be registered in Europe and (be) hopefully ready by the end of May," AIFA's Director Nicola Magrini told Italy's Radio 24.
See the latest news for the top companies producing COVID-19 vaccines, including Pfizer, Moderna, Sanofi, AstraZeneca and more.